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Abstract
The heterodimeric ABC transporter LmrCD from Lactococcus lactis is able to extrude sev-
eral different toxic compounds from the cell, fulfilling a role in the intrinsic and induced drug
resistance. The expression of the lmrCD genes is regulated by the multi-drug binding
repressor LmrR, which also binds to its own promoter to autoregulate its own expression.
Previously, we reported the crystal structure of LmrR in the presence and absence of the
drugs Hoechst 33342 and daunomycin. Analysis of the mechanism how drugs control the
repressor activity of LmrR is impeded by the fact that these drugs also bind to DNA. Here
we identified, using X-ray crystallography and fluorescence, that riboflavin binds into the
drug binding cavity of LmrR, adopting a similar binding mode as Hoechst 33342 and dauno-
mycin. Microscale thermophoresis was employed to quantify the binding affinity of LmrR to
its responsive promoter regions and to evaluate the cognate site of LmrR in the lmrCD pro-
moter region. Riboflavin reduces the binding affinity of LmrR for the promoter regions. Our
results support a model wherein drug binding to LmrR relieves the LmrR dependent repres-
sion of the lmrCD genes.
Introduction
The emergence of antibiotic resistant bacteria is becoming a serious threat for the present day
public healthcare. Several resistance mechanisms contribute to the antimicrobial resistance
phenotype of pathogenic bacteria, including enzymatic inactivation, reduced influx and substi-
tuted antibiotic targets [1]. The presence of dedicated drug extrusion transport proteins is a
major contributor to the multidrug resistance (MDR) phenotype of microbes. Certain bacterial
transport proteins have been shown to cause MDR, like AcrAB and MdfA of Escherichia coli
[2] and NorA of Staphylococcus aureus [3].
The bacterium Lactococcus lactis, which is widely used in dairy industry, contains a number
of multidrug transporters, which have been used as a model to study bacterial multidrug
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resistance [4]. A major resistance determinant in this bacterium is LmrCD [5,6], which belongs
to the ATP-binding cassette (ABC) superfamily and was shown to transport a wide variety of
drugs. Likewise, L. lactis harbors the drug transporters LmrA [7], the first identified bacterial
ABC transporter involved in drug resistance, and LmrP [8], a secondary transporter involved
in multidrug resistance. LmrCD consists of two ABC half-transporters, LmrC and LmrD,
which are homologous (27% sequence identity). Together they form a functional heterodimer.
Growth studies of L. lactis in the presence of increasing concentrations of toxic chemicals, like
rhodamine 6G and daunomycin, resulted in an enhanced MDR phenotype, which was shown
to be caused by an increased expression of the lmrCD gene [6]. A regulatory protein, LmrR,
encoded in the DNA region upstream of lmrCD was also upregulated under these conditions,
although due to a point mutation LmrR was rendered inactive causing a constitutive expression
of the lmrCD genes.
LmrR belongs to the PadR-like family of transcriptional regulators (Pfam PF03551), which
is named after a regulatory protein involved in the regulation of expression of phenolic acid
decarboxylase (pad) genes [9]. LmrR was shown to be a transcriptional repressor of lmrCD
expression and an autoregulator of its own expression [10]. Crystal structures of LmrR bound
with its ligands Hoechst 33342 (H33342) and daunomycin have been elucidated [11]. LmrR
forms a dimer with each monomer comprising a typical winged helix-turn-helix DNA binding
domain and a C-terminal helix involved in dimerization. In between the two monomers is a
large central pore that serves as the drug-binding site. It was shown that two tryptophan resi-
dues (Trp96 and Trp96’, the apostrophe denotes the other subunit in the dimer) in the central
pore are essential for the binding of ligands, which are mostly planar heterocyclic compounds.
The hydrophobic tryptophan side chains, together with other adjacent hydrophobic residues,
stabilize the ligand in the binding site. In depth analysis of the LmrR-DNA binding revealed
that LmrR interacts with two specific DNA motifs in the operator region of both lmrCD and
lmrR [12]. The LmrR binding site in the promoter/operator (p/o) region of lmrCD is a typical
PadR consensus sequence and binds LmrR with high affinity. An incomplete PadR motif is
located in the p/o of lmrR, this palindromic sequence is only weakly recognized by LmrR. A
proposed mechanism for the binding of LmrR to the p/o regions and the regulation of lmrCD
and lmrR is as followed: the binding of two LmrR dimers to PlmrCD, together with an extensive
binding of PlmrR by multiple LmrR dimers, results in a repression of lmrCD and a strong auto-
repression of lmrR. The current model is that intracellular presence of a toxic compound at rel-
atively low concentrations will cause LmrR to bind the drug, which in turn will release the
LmrR dimer from PlmrCD, thus allowing initiation of lmrCD expression. At higher drug con-
centration the multiple LmrR dimers bound to PlmrR will also be released and this derepres-
sion leads to an increased expression of both lmrCD and lmrR [12].
A major problem with the drugs that bind to LmrR is that they so far are all DNA-binding
drugs, like H33342, daunomycin and ethidium [11], which interact with DNA via groove bind-
ing or intercalation. This has precluded validation of the above model using EMSA assays. In
this study we identify, using fluorescence and X-ray crystallography, that LmrR binds the vita-
min riboflavin (RBF), which has a planar hydrophobic core structure but does not bind to
DNA like the other LmrR ligands. We then examined LmrR binding to its p/o regions in the
presence and absence of using Microscale Thermophoresis (MST). This new methodology
monitors the diffusion of particles in a microscopic temperature gradient, depending on several
biochemical properties, like charge, hydration shell and molecular mass, particles will behave
differently in the gradient [13]. MST is ideally suited to examine the interaction of DNA bind-
ing proteins with their cognate substrate DNA. We characterize the minimal binding region
necessary for LmrR interaction including the palindromic PadR motif, and analyzed the effect
of ligand binding on the interaction between LmrR and DNA.
LmrR-DNA Interaction
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Materials and Methods
Bacterial strains and growth conditions
E. coli Bl21 (DE3)C43 containing the pET17b_LmrR_strep plasmid [14] was grown in Luria
Bertani (LB) medium supplemented with 100 μg/ml ampicillin at 37°C.
Protein overproduction and purification
An overnight culture of E. coli containing pET17b_LmrR_strep was diluted in fresh LB with
ampicillin and grown till an optical density at 600 nm (OD600) of 0.8. Subsequently, IPTG was
added to a final concentration of 1 mM and cells were grown overnight at 30°C. Cells were col-
lected by centrifugation (6000 rpm, JLA10.500 rotor, 20 min, 4°C, Beckman), and resuspended
in 50 mMNaH2PO4, pH 8.0, 150 mMNaCl, and 10% glycerol and again centrifuged as before.
The resulting cell pellet was frozen at -20°C. After thawing, the pellet was resuspended in resus-
pension buffer (50 mM potassium phosphate buffer, pH 8, 150 mMNaCl, 10% glycerol) and
the cells were disrupted twice using a one-shot cell disruptor (Constant Systems, Daventry,
UK) at 13 kPsi, with 1 mM PMSF added between the two cell disruption steps to inhibit prote-
ases. Following the cell disruption, MgCl2 (final concentration 10 mM) and 1 mg/ml DNaseI
was added and the lysate was incubated for 1 hour at 30°C. Using a long needle, the cell lysate
was sheered and centrifuged (15000 rpm, SS34 rotor, 20 min, 4°C, Sorvall) to remove the
debris, whereupon the cell free extract was filtered through a 45 μm filter. The supernatant was
incubated with 6 mL Strep-tag Tactin slurry (50% Strep-tag Tactin in 50 mM potassium phos-
phate buffer, pH 8, 150 mMNaCl, 10% glycerol), for one hour on a rotary shaker at 4°C. Subse-
quently, the material was loaded on a gravity flow column, and washed 5 times with two
column volumes of resuspension buffer. LmrR-Strep was eluted with 6 column volumes of
resuspension buffer containing 2.5 mM desthiobiotin. LmrR-Strep containing fractions were
desalted to 50 mM PB, pH 8 using a Econo-PAC 10DG column (Bio-Rad) and applied to a 5
mL Heparin column (pre-equilibrated with 50 mM PB, pH 8), LmrR was eluted using a gradi-
ent of 2 M NaCl (0 to 100%, 10 min). Fractions were analyzed on a 12% SDS polyacrylamide
gel, stained with Coomassie Brilliant Blue, and the protein concentration and purity was
assessed using a UV-VIS spectrometer.
Crystallization of LmrR•RBF
LmrR was produced as an untagged protein by nisin-induced overexpression in L. lactis and
purified as described earlier [11]. The complex of LmrR with riboflavin was prepared by mixing
protein (8 mg/ml final concentration) and ligand (1.5 mM final concentration) in a 1:5 molar
ratio in a solution containing 20 mM Tris-HCl, pH 8.0, 280 mMNaCl and 1 mM EDTA. Initial
crystallization conditions were obtained by sparse-matrix screening, using the PACT and JCSG
+ commercial kits (Molecular Dimensions) and with the help of a Douglas Instruments Oryx-6
crystallization robot. Manual optimization using a sitting-drop vapor diffusion setup resulted
in a final crystallization solution, containing 0.1 M Tris-HCl, pH 8.5, 17% PEG 2000 mono-
methyl ether (MME) and 0.2 M tri-methylamine N-oxide. Crystals grew overnight from drops
containing 1 μl reservoir and 1 μl of the protein-drug mixture at 295 K.
Data collection and structure determination
X-ray diffraction data were collected at 100 K from a single flash-cooled crystal on beamline
ID23-2 at the European Synchrotron Radiation Facility (ESRF). The cryo-protecting solution
was prepared from the crystallization solution by increasing the PEG 2000 MME to 40% and
adding 0.1 M NaCl and 0.2 mM ligand. Data were processed with XDS [15] and scaled,
LmrR-DNA Interaction
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merged, and reduced with programs from the CCP4 suite [http://www.ccp4.ac.uk/]. The struc-
ture of LmrR•RBF was solved by molecular replacement with the program PHASER from the
CCP4 program suite, using a single subunit of the unliganded LmrR dimer as a search model
(PDB entry 3F8B). The model was improved in several cycles, by restrained refinement using
the programs Phenix.refine [16] and Refmac5 [17], alternated by manual model building using
COOT [18]. Subsequently, the ligand was modeled into excess density observed in the central
LmrR pore. Evaluation of the interaction geometries, real-space correlation factors and short
molecular dynamics runs was used to guide the docking of the ligand. Molecular dynamics
(200 ps) was performed with the Yasara Structure software package [http://www.yasara.org],
version 15.3.8, using included macros in combination with the YASARA2 force field. Fixed
translation libration screw (TLS) parameters were determined using the TLS motion detection
server [19] and then used in the subsequent rounds of structure refinement. In the last stages of
the refinements, water molecules were placed and retained in the model by strict criteria of dif-
ference density, B-factor cutoffs, and hydrogen-bonding capacity. The quality of the final mod-
els was checked using MolProbity [20]. Selected data collection and refinement statistics are
presented in Table 1. The coordinates and structure factors have been deposited in the PDB
with accession code 4ZZD.
Table 1. Relevant crystallographic statistics of LmrR•RBF.
Data collection
Space group P43212
Cell dimensions a, b, c (Å) 35.2, 35,2, 179.7
Resolution range* 35–2.35 (2.53–2.35)
No. of unique reﬂections 4872








No. of atoms in asymmetric unit,
average B factor (Å2)




Bond lengths (Å) 0.01
Bond angles (°) 1.01
Ramachandran analysis, validation
Preferred regions (%) 100
Allowed regions (%) 0.0
Outliers (%) 0.0
Molprobity score 1.5
*Values in parentheses refer to the highest resolution shell
doi:10.1371/journal.pone.0135467.t001
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Fluorescence-based binding assay
LmrR-RBF binding was measured by fluorescence titration using a Fluorimeter (Photon Tech-
nology International) at 25°C. To a 3-mL stirred cuvette with 100 nM purified LmrR dimer in
binding buffer (20 mM Tris-HCl, pH 8.0, 150 mMNaCl and 1 mM EDTA), RBF (37.5 μM
stock in binding buffer) was added in 2 μL steps, which results in an increase of 25 nM per
step. RBF fluorescence at 523 nm was measured after every titration step, using an excitation
wavelength of 435 nm. As a control, RBF was also titrated to the buffer lacking LmrR. After
measurement the fluorescence quenching was calculated from the change between the control
and samples containing LmrR. In addition, two independent titrations were carried out with
1.4 μM LmrR dimer in binding buffer, using a 1-ml cuvette and stepwise additions of 5 μL RBF
(112 μM stock). After correcting for dilution effects, fluorescence quenching data at the higher
protein concentration were obtained by averaging the data of the two measurements. From
each set of plotted fluorescence quenching data (at low or high protein concentration) the dis-
sociation constant was calculated by non-linear regression data fitting, using the program Sig-
maPlot [http://www.sigmaplot.com], with the equation as described in [21].
LmrR—promoter binding assay
Responsive promoter regions of both the lmrR and lmrCD genes were amplified using primers
listed in Table 2. Forward primers contain a 5’- Cy5 fluorophore modification for use in the
thermophoresis assay, modified primers were ordered from Sigma-Aldrich. A serial dilution of
purified LmrR-Strep was prepared in Binding buffer (20 mM Tris.HCl, pH 8.0; 1 mM EDTA).
To this serial dilution Cy5 –labeled promoter DNA was added to a final concentration of 50
nM and the total mixture was incubated for 30 minutes at 30°C. For ligand binding studies an
excess (50 μM) of riboflavin was added. Samples were loaded in standard treated thermophor-
esis capillaries and protein—DNA binding was measured using a Monolith NT.115 (Nanotem-
per Technologies), with 30% LED power and 40% laser power unless stated otherwise. From
the binding curves the apparent dissociation constant (Kd) was calculated using the Hill
equation.
Results
Structure determination of riboflavin-bound LmrR
Riboflavin was identified as a ligand of LmrR by co-crystallization screening. The crystal struc-
ture of the riboflavin-bound LmrR complex (LmrR•RBF) was solved by molecular replacement
and refined at 2.35 Å (Fig 1, see Table 1 for relevant crystallographic statistics). It has the same
crystal form (space group P43212) as the previously determined structure of LmrR bound to
H33342 (LmrR•H33342) [11]: a single polypeptide chain occupies the asymmetric unit with
Table 2. Primers used in this study.
Name 5’– 3’ sequence Reference
PlmrCD F Cy5- CGATTCATTCCTTACTTTAAATTC This work
PlmrCD R AAGATTGAGAATAAGGCAACCC (12)
PlmrCD R -62bp TTCTAGAGTTAAATAATGTAAAC This work
PlmrCD R muta TTCCTTTCTAGAGTTAAATAACCCAAACTAC This work
PlmrCD R noPadR ACTACTTTACATTAAATTG This work
PlmrR F CGGAGATGATTTTTTCTTATCTTATATAG (12)
PlmrR R CTCCTTGTTTTAGGACATTGAGC (12)
doi:10.1371/journal.pone.0135467.t002
LmrR-DNA Interaction
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the functional dimer being formed by a crystallographic dyad. In the electron density maps, the
polypeptide chain is well defined, except for the tip region of the β-wing (residues 70–75) and
the N- and C-termini (residues 1–5 and 109–116), which show a high degree of disorder and
were therefore excluded from the final model. Extra density in the central drug-binding pore
confirmed the presence of bound ligand, but docking of riboflavin was complicated by the
occurrence of alternative binding modes (Fig 1B). Different potential binding modes of RBF fit-
ting the electron density were tested by short 200 ps molecular dynamics runs, resulting in the
identification of two stable unique binding modes with similar predicted binding energy. These
two binding modes of RBF are related by a ~180° flip of the heterocyclic isoalloxazine moiety
relative to the ribityl side chain. In addition, each of these two binding modes has a crystallo-
graphic symmetry equivalent, due to the symmetrical position of the ligand-binding site in
Fig 1. Crystallographic analysis of RBF binding to LmrR. A) Chemical structure of RBF.B) Composite
omit 2Fo-Fc electron density for RBF in the LmrR•RBF structure calculated at 2.35 Å resolution and contoured
at 1σ. The two crystallographically independent binding conformations of RBF are shown in stick
representation with the carbon atoms colored green or cyan (oxygen and nitrogen atoms are colored red and
blue, respectively). These binding conformations differ by a ~180° rotation of the heterocyclic isoalloxazine
core relative to the ribityl moiety. The other two binding modes of RBF (shown with dark green lines) are
related to the first two by 2-fold crystallographic symmetry (the location of the crystallographic dyad is
indicated with an arrow). C) Overall structure of the LmrR•RBF dimer shown in two orientations. D) Close-up
view of the RBF binding site and ligand-interacting residues. Amino acid residues within a radius of 4.5 Å from
a ligand are shown in stick representation and labeled.
doi:10.1371/journal.pone.0135467.g001
LmrR-DNA Interaction
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LmrR•RBF on the crystallographic dyad. The occupancy of each of the four binding modes in
the crystal was estimated to be 0.25. With the four binding modes superimposed, the isoalloxa-
zine moiety of RBF shows a good fit to the averaged density, but the ribityl side chain is poorly
defined, indicating that this moiety is not strongly bound to the protein. Since the four binding
modes are highly similar, we will describe only one in detail.
Binding mode of RBF
The overall binding mode of riboflavin is similar to those of H33342 and daunomycin in the
previously determined LmrR-ligand structures (Fig 1C and 1D) [11]. The flat aromatic isoal-
loxazine ring of riboflavin slides into the center of the flat-shaped hydrophobic pore of the
LmrR dimer, in between the indole rings of the central Trp96/Trp96’ pair, while the ribityl sub-
stituent protrudes towards the pore opening. Riboflavin recognition by LmrR is likely domi-
nated by the aromatic stacking interactions of the Trp96/Trp96’ indole pair with the
heterocylic aromatic core of riboflavin. Further stabilization is provided by apolar contacts of
the ligand with hydrophobic amino acid residues in helices α1, α4, α1’ and α4’, which face the
drug binding pore and surround the central Trp96/Trp96’ pair. Near the pore opening, Asp100
may contribute to the stabilization of the hydrophilic ribityl moiety of riboflavin, by the forma-
tion of hydrogen bonds, although the observed disorder of the ribityl moiety indicates that
these interactions are quite weak. A similar situation occurs in LmrR•DAU, where Asp100 is
found near to the amino sugar substituent of DAU, but does not form strong directive interac-
tions, i.e., hydrogen bonds, as indicated by the high disorder of the substituent [11]. The disso-
ciation constant (Kd) for binding of RBF to LmrR was determined as 0.26 ± 0.08 μM, using a
fluorescence-based titration assay (Fig 2A). A similar Kd was observed at a 14-fold higher
LmrR concentration (Fig 2A, inset). It is concluded that the binding affinity of LmrR for ribo-
flavin is similar as for daunomycin (Kd = 236 ± 53 nM), but significantly weaker than for
H33342 (Kd = 21 ± 8 nM) [11].
Affinity analysis of LmrR to the lmrR and lmrCD promoters
LmrR has been shown to recognize its specific PadR p/o regions that precede the lmrR and
lmrCD, genes and interact with them in a homodimeric organization [11,12]. However, the
data also suggested that LmrR might interact with the two p/o regions in a different way. It was
suggested that LmrR binds with two dimers to the lmrR p/o region, compared to a single dimer
organization on the p/o of lmrCD [12]. This tight interaction of LmrR with its promoter causes
a strong auto-regulation and repression of the lmrCD gene expression but it remained unclear
how ligands for LmrR affect the binding. To investigate the importance of the PadR consensus
sequence on LmrR-DNA binding several DNA constructs were created containing the wild
type and modified lmrCD p/o regions (PlmrCD) (Fig 2E). Binding of LmrR to the (modified)
lmrCD promoter region was measured using microscale thermophoresis. The lmrCD promoter
DNA, synthesized as described in Agustiandari et al [12], is strongly bound by LmrR with an
apparent Kd of 82 ± 7.8 nM (Fig 2B), and a Hill coefficient of 1.78 ± 0.17 which is in agreement
with the dimeric assembly of LmrR. Binding of LmrR to the lmrR promoter DNA is less strong,
with an apparent Kd of 1.4 ± 0.1 μM, though with a higher Hill coefficient of 2.43 ± 0.19 (Fig
2C) consistent with the notion that multiple LmrR dimers bind the lmrR promoter. The bind-
ing curves exhibit an opposite orientation, which we attribute to a probable difference in the
LmrR-DNA binding mechanism [12].
Shortening of the 3’ end of the lmrCD promoter region by 62 bases slightly improved the
LmrR binding, resulting in an apparent Kd of 62 ± 7.5 nM (Fig 2B). The 5’ end of the DNA
fragment was left unchanged, since this part contains the Cy5 fluorophore and attempts to
LmrR-DNA Interaction
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Fig 2. Evaluation of the affinity of LmrR for riboflavin and DNA. A) Fluorescence quenching of riboflavin (RBF) upon titration of LmrR. The fluorescence
change was calculated and a binding curve was fitted. Concentration of LmrR in the binding assay was 100 nM (referring to dimeric protein). The inset shows
an RBF binding curve obtained with fluorescence quenching data using 1.4 μM LmrR. The indicated standard error of the mean is from two independent
experiments. B) Binding of LmrR to PlmrCD in the presence (red) and absence (black) of RBF, or to PlmrCD shortened by 62 bases (blue) in the absence of
RBF. C) Binding of LmrR to PlmrR in the presence (red) and absence (black) of RBF. PlmrR binding performed at 30% Laser power. D) Binding of LmrR to
mutated (mPadR, black squares) and truncated PadR (no PadR, red triangles) and the fitted binding curve (dashed line) that demonstrates a lack of binding.
Protein concentrations in panels B-D are for monomeric LmrR. The indicated error bars represent the standard error of the mean with n = 3. E) DNA
sequence of the lmrCD promoter region, with the palindromic PadRmotif shown in bold fond, highlighted in yellow and the transcription start site indicated in
bold font. The truncated -62 bp and truncated PadR (No PadR) products are indicated (red lines). A representation of the PadR consensus, the imperfect
PadRmotif in PlmrCD and the mutated PlmrCDwith the palindromic PadR inverted repeats shown in bold are listed at the bottom.
doi:10.1371/journal.pone.0135467.g002
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shorten the fragment from the 5’ end resulted in fluctuations in the fluorescence signal. Muta-
tion of the palindromic PadR motif (Fig 2E) resulted in an abolished LmrR binding (Fig 2D).
As a control, half of the PadR consensus was deleted. This DNA fragment did not allow LmrR
binding (Fig 2D).
Riboflavin reduces the affinity of LmrR for its responsive promoters
To investigate the effect of riboflavin on the LmrR-DNA binding we measured the interaction
of LmrR with PlmrCD and PlmrR in the presence of an excess of riboflavin. The use of the
ligand riboflavin is advantageous over the other known LmrR ligands, since it does not bind
DNA itself, in contrast to H33342 and daunomycin. Addition of riboflavin had a significant
effect on the binding of LmrR to its responsive promoter regions (Fig 2), resulting in a shift in
apparent Kd from 82.1 ± 7.8 nM to 195.4 ± 55.8 nM for PlmrCD (Fig 2B) and a shift in appar-
ent Kd from 1.4 ± 0.1 μM to 5.12 ± 0.47 μM for PlmrR (Fig 2C). Control experiments showed
that in the absence of LmrR, riboflavin has no influence on the thermophoretic behavior of
these two promoter regions (data not shown).
Discussion
The PadR consensus is crucial for the binding of LmrR to the lmrCD promoter region. Muta-
genesis of part of the palindromic motif resulted in an abolished LmrR binding, similar to the
removal of half of the PadR consensus sequence. Shortening of the 3’ tail of the DNA fragment
improved the binding of LmrR slightly, but this shorter DNA fragment probably diffuses more
easily and thereby might improve the dynamics of LmrR binding. Due to the presence of the
Cy5 fluorophore on the 5’ end of the DNA fragment and fluctuations in fluorescence signal
when modified, the 5’-end was not further shortened.
The crystallographic results and the fluorescence titration assay show that LmrR has the
ability to bind riboflavin with an affinity similar as for daunomycin, but significantly weaker
than for H33342. The relatively weak interaction is probably due to the fact that riboflavin is
not an authentic substrate of LmrCD but that it can bind LmrR because it has a similar struc-
ture as the planar heterocyclic LmrR ligands. There is no evidence that LmrCD is involved in
detoxification of riboflavin. For instance, high concentrations of riboflavin do not influence the
growth of the lmrCD deletion strain nor of the wild type L. lactis (data not shown), and thus
shows no particular toxicity. Riboflavin is an essential nutrient for L. lactis and thus present in
used growth media.
Upon addition of an excess of riboflavin to a solution containing LmrR and its DNA bind-
ing site a clear drop in binding affinity is observed, i.e., a ~2-fold decrease in LmrR binding to
PlmrCD and a ~4-fold decrease for PlmrR. The usage of the novel LmrR ligand riboflavin has
its advantages since riboflavin does not bind DNA, as confirmed by its inability to cause a ther-
mophoresis shift of the promoter DNA in absence of LmrR. A DNA-bound ligand would add
molecular mass to the complex and contribute to the thermophoretic diffusion. These data
provide direct evidence that binding of LmrR to both the PlmrCD and the PlmrR is modulated
by ligand binding to LmrR. The binding affinity of LmrR for the PlmrR is 18-fold poorer than
for PlmrCD, and this likely allows a basal level of lmrR expression. This poorer binding affinity
of LmrR for PlmrRmight be due to differences in the PadR consensus sequence compared to
the PlmrCD and is consistent with the autoregulatory mechanism of lmrR expression, requiring
expression also in the absence of drugs.
Previous atomic force microscopy analysis of LmrR-PlmrR complexes has shown that
PlmrR is bound by multiple LmrR dimers [12]. The latter may cause the opposite orientation
of the thermophoresis binding curve as compared to PlmrCD, that is bound by a single LmrR
LmrR-DNA Interaction
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dimer. These multiple LmrR dimers may bind in a cooperative manner, a hypothesis that is
supported by the observation that the hill coefficient for LmrR binding to PlmrR is higher
(2.43) compared to PlmrCD (1.78). We hypothesize that the larger LmrR complex as a whole
might not bind PlmrR as strongly as the LmrR dimer binds PlmrCD, resulting in a poorer Kd.
Comparison of the LmrR•RBF crystal structure with the previously determined structures
of LmrR bound with H33342 and DAU reveals a significant conformational flexibility of the
protein, affecting the overall geometries of both the drug and DNA binding sites (Fig 3A). The
Fig 3. Conformational differences between the three ligand-bound structures of LmrR. A)
Superpositions of the three ligand-bound dimers, emphasizing the change in relative disposition of the two
DNA-binding helices. B) Superposition of the single subunits of the three ligand-bound LmrR structures in two
different views, related by a 90° rotation. For the asymmetric LmrR•DAU dimers both subunits are included in
the superposition. The two hinge regions are indicated by arrows, and the ranges by which the orientations of
helices α1 and α4 differ are shown. The coloring is as follows: subunit A and B of LmrR•DAU, light and dark
brown, subunit A or B of LmrR•RBF, green; subunit A or B of LmrR•H33342, magenta.
doi:10.1371/journal.pone.0135467.g003
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conformational flexibility largely originates from two hinge regions in the polypeptide chain of
LmrR: in the α1-α2 loop and in the loop that connects α4 to the β-wing (Fig 3B). The observed
conformational differences support recent findings that multi-drug binding and drug-based
induction by LmrR is largely entropy-driven [22]. Binding of a ligand results in a shift of the
conformational equilibrium of LmrR towards ensembles, which are incompatible with DNA
binding, thus weakening the binding of LmrR to its promoter regions and causing its release.
Our results provide a possible explanation for the regulation of lmrCD. In the absence of
toxic compounds both PlmrCD and PlmrR are bound by LmrR dimers, although PlmrR is
probably occupied by multiple dimers simultaneously. The presence of drugs stimulates the
release of LmrR from PlmrCD, thereby activating the expression of lmrCD. The autoregulation
of lmrR expression is more complicated, as drugs also induce derepression of lmrR expression.
Summarizing, our results confirm the importance of the PadR motif for the binding of LmrR
to its responsive promoter region PlmrCD and show that riboflavin is a ligand of LmrR, which
can release LmrR from its promoter regions.
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